Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PTGX
stocks logo

PTGX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
31.42M
-81.58%
-0.263
-113.28%
51.37M
+81.39%
-0.062
-67.54%
76.37M
+1277.06%
1.038
-288.79%
Estimates Revision
The market is revising Downward the revenue expectations for Protagonist Therapeutics, Inc. (PTGX) for FY2025, with the revenue forecasts being adjusted by -1.82% over the past three months. During the same period, the stock price has changed by 44.28%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.82%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-16.95%
In Past 3 Month
Stock Price
Go Up
up Image
+44.28%
In Past 3 Month
Wall Street analysts forecast PTGX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTGX is 87.31 USD with a low forecast of 65.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast PTGX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTGX is 87.31 USD with a low forecast of 65.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 87.330
sliders
Low
65.00
Averages
87.31
High
112.00
Current: 87.330
sliders
Low
65.00
Averages
87.31
High
112.00
Goldman Sachs
Neutral
maintain
$47 -> $65
2025-11-10
Reason
Goldman Sachs
Price Target
$47 -> $65
2025-11-10
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on Protagonist Therapeutics (PTGX) to $65 from $47 and keeps a Neutral rating on the shares. Protagonist reported Q3 results with GAAP EPS of (62c), supported by $678.8M in cash expected to fund operations through year end 2028 without additional capital raises, the analyst tells investors in a research note. Despite a 20% stock lift following a Wall Street Journal report on potential Johnson & Johnson (JNJ) interest, the current price appears disconnected from fundamentals, and remaining unpartnered assets remain early-stage, the firm adds.
Citi
Buy
maintain
$96 -> $98
2025-11-10
Reason
Citi
Price Target
$96 -> $98
2025-11-10
maintain
Buy
Reason
Citi raised the firm's price target on Protagonist Therapeutics to $98 from $96 and keeps a Buy rating on the shares.
JPMorgan
Brian Cheng
Overweight
maintain
$68 -> $81
2025-11-07
Reason
JPMorgan
Brian Cheng
Price Target
$68 -> $81
2025-11-07
maintain
Overweight
Reason
JPMorgan analyst Brian Cheng raised the firm's price target on Protagonist Therapeutics to $81 from $68 and keeps an Overweight rating on the shares.
Clear Street
Buy
upgrade
$74 -> $91
2025-11-07
Reason
Clear Street
Price Target
$74 -> $91
2025-11-07
upgrade
Buy
Reason
Clear Street raised the firm's price target on Protagonist Therapeutics to $91 from $74 and keeps a Buy rating on the shares. The firm updated the company's model post the Q3 report.
Citizens JMP
NULL -> Outperform
maintain
$69 -> $102
2025-11-07
Reason
Citizens JMP
Price Target
$69 -> $102
2025-11-07
maintain
NULL -> Outperform
Reason
Citizens JMP raised the firm's price target on Protagonist Therapeutics to $102 from $69 and keeps an Outperform rating on the shares. Protagonist Therapeutics has proven it can discover and develop differentiated pipeline candidates and the next wave of candidates are entering the clinic now, the analyst tells investors in a research note.
Barclays
NULL -> Overweight
upgrade
$72 -> $88
2025-11-07
Reason
Barclays
Price Target
$72 -> $88
2025-11-07
upgrade
NULL -> Overweight
Reason
Barclays raised the firm's price target on Protagonist Therapeutics to $88 from $72 and keeps an Overweight rating on the shares following the Q3 report.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Protagonist Therapeutics Inc (PTGX.O) is 63.81, compared to its 5-year average forward P/E of -19.90. For a more detailed relative valuation and DCF analysis to assess Protagonist Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-19.90
Current PE
63.81
Overvalued PE
27.21
Undervalued PE
-67.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
39.98
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
248.87
Undervalued EV/EBITDA
-168.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
40.93
Current PS
0.00
Overvalued PS
68.90
Undervalued PS
12.96
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PTGX News & Events

Events Timeline

(ET)
2025-11-06
17:18:12
Protagonist Therapeutics Announces Q3 EPS of 62c, Below Consensus Estimate of 64c
select
2025-10-27 (ET)
2025-10-27
11:06:02
Clear Street recognizes 'unparalleled commercial potential' for Protagonist's icotrokinra.
select
2025-10-27
07:40:49
Protagonist Therapeutics Reveals Icotrokinra Data for Ulcerative Colitis and Plaque Psoriasis
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-28NASDAQ.COM
Transcript of Protagonist (PTGX) Earnings Call
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
4.0
11-26NASDAQ.COM
Protagonist Therapeutics Achieves Analyst Price Target

  • Current Stock Performance: Protagonist Therapeutics Inc (PTGX) shares have surpassed the average analyst 12-month target price of $89.77, trading at $89.86/share, prompting potential analyst reactions regarding valuation adjustments.

  • Analyst Target Range: There are 13 analyst targets for PTGX, with a wide range from a low of $65.00 to a high of $112.00, indicating varying opinions on the stock's future performance.

  • Investor Considerations: The crossing of the average target price signals investors to evaluate whether the stock is on a path to higher targets or if it has become overvalued, suggesting a potential need to reassess their positions.

  • Analyst Rating System: The article references an average rating system for analysts covering PTGX, where ratings range from 1 (Strong Buy) to 5 (Strong Sell), reflecting the collective sentiment towards the stock.

[object Object]
Preview
4.0
11-11Benzinga
Citigroup Reaffirms Buy Rating on Protagonist Therapeutics and Increases Price Target to $98

  • Real-time Intelligence: Benzinga Pro offers fast and accurate stock market intelligence to help traders make informed decisions.

  • Exclusive Stories: The platform provides exclusive news stories generated by Benzinga reporters, enhancing the trading experience for its users.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Protagonist Therapeutics Inc (PTGX) stock price today?

The current price of PTGX is 87.33 USD — it has increased 1.46 % in the last trading day.

arrow icon

What is Protagonist Therapeutics Inc (PTGX)'s business?

Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

arrow icon

What is the price predicton of PTGX Stock?

Wall Street analysts forecast PTGX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTGX is 87.31 USD with a low forecast of 65.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Protagonist Therapeutics Inc (PTGX)'s revenue for the last quarter?

Protagonist Therapeutics Inc revenue for the last quarter amounts to 4.71M USD, increased 0.79 % YoY.

arrow icon

What is Protagonist Therapeutics Inc (PTGX)'s earnings per share (EPS) for the last quarter?

Protagonist Therapeutics Inc. EPS for the last quarter amounts to -0.62 USD, increased 14.81 % YoY.

arrow icon

What changes have occurred in the market's expectations for Protagonist Therapeutics Inc (PTGX)'s fundamentals?

The market is revising Downward the revenue expectations for Protagonist Therapeutics, Inc. (PTGX) for FY2025, with the revenue forecasts being adjusted by -1.82% over the past three months. During the same period, the stock price has changed by 44.28%.
arrow icon

How many employees does Protagonist Therapeutics Inc (PTGX). have?

Protagonist Therapeutics Inc (PTGX) has 126 emplpoyees as of December 05 2025.

arrow icon

What is Protagonist Therapeutics Inc (PTGX) market cap?

Today PTGX has the market capitalization of 5.46B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free